Latest Articles

  • Identifying serious causes of back pain: Cancer, infection, fracture
    Krzysztof Siemionow, MD, Michael Steinmetz, MD, Gordon Bell, MD, Hakan Ilaslan, MD and Robert F. McLain, MD
    Cleveland Clinic Journal of Medicine August 2008, 75 (8) 557-566;

    Most patients with back pain have a benign condition, but tumors, infections, and fractures must be considered during an initial evaluation because overlooking them can have serious consequences.

  • Congenital long QT syndrome: Considerations for primary care physicians
    Congenital long QT syndrome: Considerations for primary care physicians
    Ethan Levine, DO, Spencer Z. Rosero, MD, Adam S. Budzikowski, MD, PhD, Arthur J. Moss, MD, Wojciech Zareba, MD, PhD and James P. Daubert, MD
    Cleveland Clinic Journal of Medicine August 2008, 75 (8) 591-600;

    We now know more about the genetic basis of different types of long QT syndrome and their clinical implications. In one type, patients can die suddenly during exercise, in another, during inactivity, and in a third, when startled, such as by an alarm clock. The right therapy can dramatically reduce the risk.

  • The gout diagnosis
    Brian F. Mandell, MD, PHD and Robin K. Dore, MD
    Cleveland Clinic Journal of Medicine July 2008, 75 (7 suppl 5) S17-S21;
  • The practical management of gout
    Brian F. Mandell, MD, PHD, H. Ralph Schumacher, MD and Lan X. Chen, MD, PhD
    Cleveland Clinic Journal of Medicine July 2008, 75 (7 suppl 5) S22-S25;
  • Epidemiology of gout
    Brian F. Mandell, MD, PHD and Arthur L. Weaver, MD, MS
    Cleveland Clinic Journal of Medicine July 2008, 75 (7 suppl 5) S9-S12;
  • Clinical manifestations of hyperuricemia and gout
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine July 2008, 75 (7 suppl 5) S5-S8;
  • Interpreting the Enhance Trial
    Michael H. Davidson, MD
    Cleveland Clinic Journal of Medicine July 2008, 75 (7) 479-491;

    The impact of the ENHANCE trial reveals more about the political climate than it does about the effects of ezetimibe on the progression of atherosclerosis.

  • The pathogenesis of gout
    Brian F. Mandell, MD, PHD and H. Ralph Schumacher, MD
    Cleveland Clinic Journal of Medicine July 2008, 75 (7 suppl 5) S2-S4;
  • A drug, a concept, and a clinical trial on trial
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine July 2008, 75 (7) 470;

    The ENHANCE trial, evaluating the addition of a second hypocholesterolemic drug (ezetimibe) to a statin using two surrogate end points in a relatively small number of patients, hit the national news when the two surrogates didn’t match up.

  • Confessions of a goutophile
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine July 2008, 75 (7 suppl 5) S1;

Pages